Get 40% off of select print and eBooks in Engineering & Materials Science!

Developments in Cardiovascular Medicine

Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents

Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 & 28, 1988

Editors: Morganroth, J., Moore, E. Neil (Eds.)

Free Preview

Buy this book

eBook $169.00
price for USA in USD (gross)
  • ISBN 978-1-4613-1605-3
  • Digitally watermarked, DRM-free
  • Included format: PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $319.00
price for USA in USD
  • ISBN 978-0-7923-0294-0
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
Softcover $219.99
price for USA in USD
  • ISBN 978-1-4612-8888-6
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
About this book

The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of acute myocardial ischemia and infarction, one must carefully consider the potential risks of such agents in regards to their potential benefits. The time when a thrombolytic agent should be administered to maximize benefit as well as how one defines a dose response relationship using intravenous critical care medicines were discussed as important clinical trial issues. The benefit versus risk data on currently available thrombolytic agents was reviewed and the potential roles for adjunctive agents addressed. Overall strategies regarding post- x thrombolytic care and relationships to sudden cardiac death were also detailed. The panel discussion sections provided a comprehensive view of the current thinking of the various participating groups in this symposium. Sudden cardiac death remains the number one cause of mortality in western industrialized societies.

Table of contents (17 chapters)

Table of contents (17 chapters)
  • Measurement of Infarct Size: Effect of Reperfusion with Arterial Blood

    Pages 3-13

    Jennings, Robert B., M.D. (et al.)

  • Pitfalls in the Design and Evaluation of Clinical Trials of Intravenously Administered Cardiovascular Drugs

    Pages 15-22

    Packer, Milton, M.D.

  • The Relative Benefit and Risks of Intravenous Streptokinase and Tissue Plasminogen Activator in Acute Myocardial Infarction

    Pages 23-28

    Ross, Allan M., M.D.

  • New Agents and New Insights for Thrombolytic Therapy in Acute Myocardial Infarction: Focus on Anistreplase, Urokinase, and Prourokinase

    Pages 29-46

    Anderson, Jeffrey L., M.D.

  • Myocardial Reperfusion: Role of Adjunctive Agents to Improve Reperfusion and Prevent Reperfusion Injury

    Pages 47-58

    Pitt, B. (et al.)

Buy this book

eBook $169.00
price for USA in USD (gross)
  • ISBN 978-1-4613-1605-3
  • Digitally watermarked, DRM-free
  • Included format: PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $319.00
price for USA in USD
  • ISBN 978-0-7923-0294-0
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
Softcover $219.99
price for USA in USD
  • ISBN 978-1-4612-8888-6
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
Loading...

Services for this Book

Recommended for you

Loading...

Bibliographic Information

Bibliographic Information
Book Title
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents
Book Subtitle
Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 & 28, 1988
Editors
  • J. Morganroth
  • E. Neil Moore
Series Title
Developments in Cardiovascular Medicine
Series Volume
100
Copyright
1989
Publisher
Springer US
Copyright Holder
Kluwer Academic Publishers
eBook ISBN
978-1-4613-1605-3
DOI
10.1007/978-1-4613-1605-3
Hardcover ISBN
978-0-7923-0294-0
Softcover ISBN
978-1-4612-8888-6
Series ISSN
0166-9842
Edition Number
1
Number of Pages
XVIII, 298
Topics